Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee
22 févr. 2018 16h01 HE
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania
20 févr. 2018 16h01 HE
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the 2018 RBC Capital Markets Healthcare Conference
15 févr. 2018 08h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference
09 févr. 2018 08h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces $100 Million Debt Financing from Athyrium Capital Management
02 janv. 2018 08h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at BMO Capital Markets Prescription for Success Healthcare Conference
07 déc. 2017 16h05 HE
|
OptiNose, Inc.
YARDLEY, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive...
Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights
27 nov. 2017 16h05 HE
|
OptiNose, Inc.
YARDLEY, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
Optinose to Report Third Quarter 2017 Financial Results and Operational Highlights on November 27, 2017
20 nov. 2017 07h30 HE
|
OptiNose, Inc.
YARDLEY, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that the Company will...
Optinose to Present at Piper Jaffray Healthcare Conference
17 nov. 2017 07h30 HE
|
OptiNose, Inc.
YARDLEY, Pa., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive...
Optinose to Present at Jefferies 2017 London Healthcare Conference
08 nov. 2017 08h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive...